Clinical Safety & Treatment Protocol Medical Screening: DHA-licensed physicians review medical history, cardiovascular health, medications, and treatment suitability before starting PT-141 therapy
Side effects - primarily gastrointestinal (nausea, vomiting, constipation, and abdominal discomfort) - are well-documented in clinical trial populations and are typically most pronounced during the initial titration phase before the body adapts to rising drug concentrations, which is why the standard-of-care approach involves gradual dose escalation over several weeks or months rather than starting at full therapeutic dose
The rationale mirrors how GHK-Cu-led protocols are typically framed: front-load exposure to establish tissue effects, then step frequency down to a maintenance rhythm that sustains them
N., Li, H
The most common side effects of tesamorelin include injection site reactions like redness or swelling, joint or muscle pain, nausea, fatigue, headaches, and difficulty sleeping
Storage conditions Do not store at a temperature above 30 C